Meningococcal Vaccine: Immune Response Study in Transgender and Cisgender Adults

We are investigating how healthy transgender and cisgender individuals aged 18 to 50 respond to the meningococcal serogroup B vaccine. This study aims to understand potential differences in immune responses between these groups.

6-12 monthsMonitoring phase (IV)No PlaceboCost ReimbursementInvestigational MedicinesInjectionInfectious DiseasesInternal Medicine

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Bexsero
Bexsero is a vaccine that helps prevent group B bacterial infections that can cause severe brain or blood infections.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Aluminium Hydroxide
Aluminium hydroxide is a substance that neutralizes stomach acid to relieve heartburn, indigestion, and acid-related discomfort.
Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium Hydroxide
Outer membrane vesicles from Neisseria meningitidis group B are a vaccine ingredient used to prevent meningococcal group B infections.
Recombinant Neisseria Meningitidis Group B Fhbp Fusion Protein Produced In E. Coli Cells By Recombinant Dna Technology Adsorbed On Aluminium Hydroxide
Recombinant Neisseria meningitidis group B FHbp fusion protein is a vaccine ingredient that helps the immune system protect against meningococcal group B infection.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Outer Membrane Vesicles

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Alk (Alutard Sq)
Alk-Depot Sq 802
Allergovit

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Universiteit Gent
Vakgroep Diagnostische Wetenschappen
Ledeberg, Belgium
Sponsor: Universiteit Gent
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.